Mood-Stabilizing Effect of Twice-Weekly Administration of Fluoxetine in a Bipolar II Disorder Patient.

about

Mood-Stabilizing Effect of Twice-Weekly Administration of Fluoxetine in a Bipolar II Disorder Patient.

Item

http://www.wikidata.org/entity/Q42612203

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Mood-Stabilizing Effect of Twi ...... a Bipolar II Disorder Patient.

@en

Mood-Stabilizing Effect of Twi ...... a Bipolar II Disorder Patient.

@nl

type

Item

label

Mood-Stabilizing Effect of Twi ...... a Bipolar II Disorder Patient.

@en

Mood-Stabilizing Effect of Twi ...... a Bipolar II Disorder Patient.

@nl

prefLabel

Mood-Stabilizing Effect of Twi ...... a Bipolar II Disorder Patient.

@en

Mood-Stabilizing Effect of Twi ...... a Bipolar II Disorder Patient.

@nl

P1476

Mood-Stabilizing Effect of Twi ...... a Bipolar II Disorder Patient.

@en

P2093

Amir Shabani

http://www.w3.org/2001/XMLSchema#string

P2860

Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial

Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania.

"Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder.

Bipolar spectrum disorders. New perspectives

Antidepressant monotherapy for bipolar type II major depression.

Bipolar II disorder: a review.

Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression.

The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.

Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder.

Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder.

P304

392-393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4088/PCC.V09N0511A

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17998961

http://www.w3.org/2001/XMLSchema#string

P932

2040288

http://www.w3.org/2001/XMLSchema#string